Strong Top-Line Growth
Total net revenue grew 19% year-over-year to $317 million in Q1 2026.
SUBLOCADE Revenue Acceleration
Total SUBLOCADE net revenue increased 32% year-over-year to $232 million (U.S. SUBLOCADE up 33% to $218 million), driven by 20% dispense unit growth and favorable price/mix.
Patient and Prescriber Momentum
Record new patient starts of ~31,800 in Q1 (up 29% YoY); over 500,000 U.S. patients prescribed SUBLOCADE since launch (nearly 25% added in the last 5 quarters); total U.S. SUBLOCADE patients treated in last 12 months: 191,600. Active SUBLOCADE prescribers grew 19% YoY; prescribers treating 5+ patients grew 20% YoY.
Adjusted EBITDA and Margin Expansion
Adjusted EBITDA was a record $164 million in Q1, up 112% YoY, with margin improvement of 23 percentage points. 2026 adjusted EBITDA guidance raised to $620–$660 million (midpoint $640M), up ~50% YoY and implying a ~51% margin.
Raised 2026 Financial Guidance
Total 2026 net revenue guidance raised to $1.215–$1.285 billion (midpoint up ~1% vs 2025). SUBLOCADE 2026 net revenue guidance raised to $950–$990 million (midpoint +13% YoY). Company now expects SUBLOCADE dispense unit growth to accelerate to mid-teens in 2026 (from 7% in 2025).
Operating Efficiency and Cost Reduction
Non-GAAP operating expenses were $116 million in Q1, down 21% YoY due to headcount reductions, R&D/medical affairs restructuring, and footprint consolidation.
Capital Deployment and Balance Sheet Improvements
Completed $500 million senior convertible notes offering (used mostly to repay $333 million term loan), lowering interest to 0.625% from 9.5%. Repurchased $125 million of shares (4 million shares at $31.45 avg); remaining buyback capacity reported (~$275M). Q1 gross cash & investments: $201 million; projected 2026 leverage ~0.8x and ~$340 million expected cash flow from operations.
Commercial Execution and DTC Impact
DTC campaign 'Move Forward in Recovery' showing early impact: >1,200 new CRM enrollments/month, >8,300 engaged consumers since launch, >30,000 Find-a-Provider searches in Q1, and paid search volumes above pre-campaign levels. Specialty pharmacy enhanced service agreements and improved dispense yields underway.